SLE Biomarker Panel Scoring for Misdiagnosis Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring Systemic Lupus Erythematosus (SLE) are unreliable due to the lack of a definitive test, leading to misdiagnosis and inadequate monitoring of disease activity, as the existing criteria are fallible and symptoms can evolve over time, causing challenges in identifying and treating the condition.
Innovation Solution
A method involving calculating an SLE risk score based on levels of erythrocyte C4d (EC4d), B-cell C4d (BC4d), and anti-nuclear antibodies (ANA) markers, optionally with additional rule-out markers, using logistic regression analysis to adjust and combine marker levels for improved diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic criteria are used for SLE, then diagnosis can be made based on clinical symptoms, but the diagnosis is fallible and lacks reliability
Solution Approach 1:
The patent replaces the conventional mechanical/clinical evaluation system with a molecular/biomarker-based diagnostic system. By measuring specific biomarkers (C4d on erythrocytes, C4d on B cells, and ANA levels) in blood samples, the system substitutes subjective clinical criteria with objective, quantifiable molecular data to improve diagnostic reliability and precision.
Solution Approach 2:
The patent changes the diagnostic parameters from clinical symptom assessment to quantitative biomarker measurement. By using specific measurable parameters (biomarker levels, antibody concentrations) and establishing cutoff values, the system transforms qualitative diagnosis into quantitative assessment, thereby improving both reliability and precision of SLE diagnosis.
2Adaptability or versatility
If multiple clinical criteria are evaluated, then diagnosis coverage is broad, but the complexity of diagnosis increases
Solution Approach 1:
The patent segments the complex diagnostic process into distinct, measurable components: C4d on erythrocytes, C4d on B cells, and ANA levels. Each component can be measured independently using standardized laboratory assays, and the results are combined using a simplified scoring system, thereby reducing overall diagnostic complexity while maintaining broad coverage.
Solution Approach 2:
The patent introduces biomarkers as intermediary elements between the disease state and diagnostic detection. These biomarkers serve as measurable proxies for complex disease processes, allowing clinicians to assess SLE status through simple blood tests rather than complex multi-criteria evaluation, thus reducing diagnostic complexity.
3Measurement precision
If traditional monitoring methods are used, then disease activity can be assessed clinically, but monitoring accuracy is insufficient
Solution Approach 1:
The patent substitutes clinical monitoring methods with molecular monitoring by measuring biomarker levels (C4d, ANA) in blood samples. This molecular approach provides more accurate and reliable monitoring of disease activity compared to subjective clinical assessment, as it directly detects pathophysiological changes at the molecular level.
Solution Approach 2:
The patent establishes a feedback mechanism where biomarker levels are continuously measured and compared against cutoff values to assess disease activity. This quantitative feedback allows for objective monitoring of disease progression or response to treatment, improving both accuracy and reliability of monitoring.
4Reliability
If clinical symptoms are monitored over time, then disease evolution can be detected, but the time required for diagnosis is extended
Solution Approach 1:
The patent performs preliminary diagnostic action by measuring biomarkers early in the clinical course, before full diagnostic criteria are met. By detecting biomarker patterns that predict SLE development, the system can initiate diagnosis and treatment earlier, reducing the time required to accumulate sufficient clinical criteria while maintaining high diagnostic accuracy.
Data Source
AI summary
Biomarkers, such as erythrocyte-bound C4d. B-lymphocyte-bound C4d. anti-nuclear antibody. Sjögren's syndrome type B antigen, Scl-70 antibody. Jo-1 antibody, and anti-centromere protein B. can be used to diagnose. prognose, monitor, and treat subjects having systemic lupus erythematosus.